Healthcare Technologies Ltd. (NASDAQ:HCTL)
Industry: Healthcare

Listed 70 Consecutive Market Days. On List as of 07/17/2006 Through 10/24/2006

Healthcare Technologies Ltd. (Healthcare), incorporated in May 1988, is engaged in developing, manufacturing and marketing clinical diagnostic test kits. The Company also provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites in Israel and worldwide. It is also engaged in the production and marketing of molecular biology-based gene screening tools for the detection of certain gene-associated disorders in humans, including prenatal testing for diseases, such as cystic fibrosis, gaucher and other diseases, and testing for predisposition to diseases, such as breast, ovarian and colon cancer, thrombosis and certain cardiovascular diseases. The Company distributes its own products, as well as products from other manufacturers, including some of the vitro diagnostics and scientific companies. Healthcare's manufacturing activities are conducted by Savyon Diagnostics Ltd. (Savyon). The Company markets products, reagents and systems to clinical diagnostic laboratories and doctors' offices in Israel through the Gamidor Diagnostics Ltd (Gamidor). It markets instruments, devices, systems, compounds, reagents and services to biotechnology researchers in Israel through Danyel Biotech Ltd. (Danyel). Savyon is engaged in the serological diagnosis of chlamydial infections. Savyon also manufactures immunoassays for the diagnosis of infectious diseases for microplate-based enzyme immunoassays (EIA). Savyon provides diagnostic tools to laboratory professionals and point-of-care locations in Israel and worldwide. In addition, Savyon markets kits for the diagnosis of certain infectious diseases in the over-the-counter market in the United States. Savyon holds rights to certain products in the vitro diagnostics healthcare field. Savyon also manufactures immunoassays for detection of certain pathogens of sexually transmitted diseases (STD), particularly for the serological diagnosis of chlamydial infections and of respiratory tract infections, and sophisticated devices for the detection of urinary tract infections. Savyon's products include enzyme-linked immunosorbent assay test kits, micro-immunofluorescence techniques (MIF), immuno peroxidase assays and Uriscreen. Savyon has also been engaged in the production of molecular biology-based gene screening tools for the detection of gene-associated disorders in humans, which facilitates early diagnosis, treatment or medical intervention. GamidaGen developed Pronto, a molecular biology-based technology for the detection of single nucleotide polymorphisms in deoxyribonucleic acid (DNA), which is used for genetic screening and testing of certain human genetic disorders. Savyon's diagnostic kits are designed to conduct diagnostic tests utilizing EIA and MIF, and rapid tests. Immunoassays are diagnostic techniques, which detects the presence or absence of a specific disease by measuring the amount of a specific antibody (indirect tests) or antigen (direct tests) in a patient's blood sample or other body fluids through the introduction of a specific antigen or antibody into the sample. Savyon manufactures specific immunoassays, SeroCT, SeroCP and SeroCP Quant, which are utilized for the detection of antibodies specific to chlamydia. Chlamydia is an intracellular bacterium that causes acute and chronic respiratory and STD in mammalian and avian species. Savyon also manufactures SeroFIA, SeroMP, SeroPertussis, Quickstripe, Uriscreen, Chlamydia IgG, IgA and IgM diagnostic kits. The Company develops pre-disposition tests for certain diseases through three-kit panel, which tests for mutations in genes associated with pre-disposition to thrombosis, such as Factor V Leiden (Factor V), which is the common hereditary blood coagulation disorder, the prothrombin (Factor II) mutation 20210A, which is a major risk factor for venous thrombosis and certain arterial thrombotic conditions, and the methylenetetrahydrofolate reductase mutation 677C>T (MTHFR). It has also developed further tests associated with pre-disposition to other diseases, su

Current Quote*
Last: $Unk
Change: 0.000
Book: $Unk
Volume: Unk

As Of: 10/07 00:00 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol HCTL

  • No BuyIns.Net Alerts Available for HCTL

Graphs for HCTL


3 Month Graph


6 Month Graph


1 Year Graph